Covidien Hernia Mesh (No. II)

This docket consolidates claims that Covidien-manufactured hernia mesh products caused injury through mechanisms including chronic pain, infection, adhesion, bowel obstruction, or mesh migration, requiring revision surgery in many cases. Centralized in June 2022 before Judge Patti B. Saris in the District of Massachusetts, the docket has grown rapidly to 2,453 pending actions out of 2,459 total filed — a near-total pending rate indicating this is a large, still-forming docket rather than one that has begun resolving claims at scale.

For a funder, a docket this size and this early in its resolution curve presents both opportunity and a distinct risk profile. The claim volume supports genuine portfolio-scale underwriting for a firm with a meaningful book of hernia-mesh clients, and hernia mesh as a device category has an extensive general body of prior MDL litigation (in other manufacturers' dockets) establishing common causation theories around mesh-related complications, which can inform diligence even without a bellwether verdict specific to this Covidien docket yet. That said, claim-specific causation still requires verifying the plaintiff's specific mesh product, implant date, and complication history against this docket's own developing record.

Medical-lien exposure is meaningful given that hernia-mesh complications often require revision surgery and extended treatment, and any funding structure should account for that exposure against expected recovery. Given the docket's scale and its position early in the resolution curve, portfolio-level inventory finance under Criterica Capital's mass tort finance line is well suited to a firm building an inventory here, with duration assumptions calibrated to a docket that has not yet reached bellwether trials or a settlement framework in this specific proceeding. A structural brief on this docket is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.